Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: An analysis of 31 cases with confocal laser scanning microscopy

Bone

Volumn 45, Issue 3, 2009, Pages 406-413

  Favia, G ^a   Pilolli, G P ^a   Maiorano, E ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Bisphosphonates; Bone necrosis; Histomorphometry; Jawbones; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FUCHSINE; LEUPRORELIN; MELPHALAN; METHACRYLIC ACID METHYL ESTER; METHOTREXATE; METHYLENE BLUE; PAMIDRONIC ACID; THALIDOMIDE; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BASOPHIL; BONE BIOPSY; BONE BLOOD FLOW; BONE DEMINERALIZATION; BONE DEVELOPMENT; BONE METABOLISM; BONE REMODELING; BONE STRUCTURE; BREAST CANCER; CELL DEATH; CELL NUCLEUS; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFOCAL LASER MICROSCOPY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEBRIDEMENT; EMBEDDING; FEMALE; HAVERSIAN CANAL; HISTOCHEMISTRY; HISTOPATHOLOGY; HUMAN; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; JAW OSTEONECROSIS; KIDNEY CANCER; LARYNX CANCER; MALE; MICROSCOPY; MORPHOMETRICS; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PANORAMIC RADIOGRAPHY; PROSTATE CANCER; SOFT TISSUE; THYROID CANCER; TISSUE FIXATION; TRABECULAR BONE; UTERUS CANCER; VASODILATATION;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; OSTEOBLASTS; OSTEOCLASTS; OSTEONECROSIS;

EID: 67949106446     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.05.008     Document Type: Article

References (53)

1. McClung M.R. Bisphosphonates. Endocrinol. Metab. Clin. North. Am. 32 (2003) 253-271
2. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18 (1996) 75-85
3. Santini D., Vespasiani Gentilucci U., Vincenzi B., Picardi A., Vasaturo F., La Cesa A., et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann. Oncol. 14 (2003) 1468-1476
4. Boissier S., Ferreras M., Peyruchaud O., Magnetto S., Ebetino F.H., Colombel M., et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60 (2000) 2949-2954
5. van der Pluijm G., Vloedgraven H., van Beek E., van der Wee-Pals L., Lowik C., and Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Invest. 98 (1996) 698-705
6. Boissier S., Magnetto S., Frappart L., Cuzin B., Ebetino F.H., Delmas P.D., et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57 (1997) 3890-3894
7. Lee M.V., Fong E.M., Singer F.R., and Guenette R.S. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 61 (2001) 2602-2608
8. Riebeling C., Forsea A.M., Raisova M., Orfanos C.E., and Geilen C.C. The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br. J. Cancer 87 (2002) 366-371
9. Wood J., Bonjean K., Ruetz S., Bellahcene A., Devy L., Foidart J.M., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther. 302 (2002) 1055-1061
10. Santini D., Vincenzi B., Dicuonzo G., Avvisati G., Massacesi C., Battistoni F., et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res. 9 (2003) 2893-2897
11. Kunzmann V., Bauer E., and Wilhelm M. γ/δ T cell stimulation by pamidronate. N. Engl. J. Med. 340 (1999) 737-738
12. Coleman R.E. Skeletal complications of malignancy. Cancer 80 (1997) 1588-1594
13. Conte P., and Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9 (2004) 28-37
14. Ali S.M., Esteva F.J., Hortobagyi G., Harvey H., Seaman J., Knight R., et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J. Clin. Oncol. 19 (2001) 3434-3437
15. Lugassy G., Shaham R., Nemets A., Ben-Dor D., and Nahlieli O. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am. J. Med. 117 (2004) 440-441
16. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral. Maxillofac. Surg. 61 (2003) 1115-1117
17. Migliorati C.A. Bisphosphanates and oral cavity avascular bone necrosis. J. Clin. Oncol. 21 (2003) 4253-4254
18. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral. Maxillofac. Surg. 62 (2004) 527-534
19. Melo M.D., and Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J. Can. Dent. Assoc. 71 (2005) 111-113
20. Greenberg M.S. Intravenous bisphosphonates and osteonecrosis. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 98 (2004) 259-260
21. Purcell P.M., and Boyd I.W. Bisphosphonates and osteonecrosis of the jaw. Med. J. Aust. 182 (2005) 417-418
22. Schwartz H.C. Bisphosphonate-associated osteonecrosis of the jaws. J. Oral. Maxillofac. Surg. 63 (2005) 1555-1556
23. Vannucchi A.M., Ficarra G., Antonioli E., and Bosi A. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br. J. Hematol. 128 (2005) 738
24. Bagan J.V., Murillo J., Jimenez Y., Poveda R., Milian M.A., Sanchis J.M., et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J. Oral. Pathol. Med. 34 (2005) 120-123
25. Hellstein J.W., and Marek C.L. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?. J. Oral. Maxillofac. Surg. 63 (2005) 682-689
26. Maerevoet M., Martin C., and Duck L. Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. 353 (2005) 99-100
27. Durie B.G., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. 353 (2005) 100
28. Woo S.B., Hande K., and Richardson P.G. Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. 353 (2005) 100-101
29. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J. Am. Dent. Assoc. 137 (2006) 1144-1150
30. Todisco M., and Trisi P. Bone mineral density and bone histomorphometry are statistically related. Int. J. Oral. Maxillofac. Implants 20 (2005) 898-904
31. Pilolli G.P., Lucchese A., Maiorano E., and Favia G. New approach for static bone histomorphometry: confocal laser scanning microscopy of maxilla-facial normal bone. Ultrastruct. Pathol. 32 (2008) 189-192
32. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2 (1987) 595-610
33. Lozupone E., and Favia A. The structure of the trabeculae of cancellous bone. 2. Long bones and mastoid. Calcif. Tissue Int. 46 (1990) 367-372
34. Greiner S., Kadow-Romacker A., Schmidmaier G., Wildemann B., Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating. J Biomed Mater Res A, doi:10.1002/jbm.a.32245.
35. Panzavolta S., Torricelli P., Bracci B., Fini M., and Bigi A. Alendronate and Pamidronate calcium phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast cells. J. Inorg. Biochem. 103 (2009) 101-106
36. Pampu A.A., Dolanmaz D., Tüz H.H., Avunduk M.C., and Kişnişci R.S. Histomorphometric evaluation of the effects of zoledronic acid on mandibular distraction osteogenesis in rabbits. J. Oral. Maxillofac. Surg. 66 (2008) 905-910
37. Boanini E., Torricelli P., Gazzano M., Giardino R., and Bigi A. Alendronate-hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells. Biomaterials 29 (2008) 790-796
38. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., and Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. 100 (1997) 1475-1480
39. Ott S.M. Long-term safety of bisphosphonates. J. Clin. Endocrinol. Metab. 90 (2005) 1897-1899
40. Kaye M. When is it an osteoclast?. J. Clin. Pathol. 37 (1984) 398-400
41. Migliorati C.A., Schubert M.M., Peterson D.E., and Seneda L.M. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104 (2005) 83-93
42. Giraudo E., Inoue M., and Hanahan D. An amino-bisphosphonates targets MMP-9 expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 114 (2004) 623-633
43. Deckers M.M., Van Beek E.R., Van Der Pluijm G., Wetterwald A., Van Der Wee-Pals L., Cecchini M.G., et al. Dissociation of angiogenesis and octeoclastogenesis during endochondral bone formation in neonatal mice. J. Bone Miner. Res. 17 (2002) 998-1007
44. Santini D., Vincenzi B., Avvisati G., Dicuonzo G., Battistoni F., Gavasci M., et al. Pamidronate induces modification of circulating angiogenetic factors in cancer patients. Clin. Cancer Res. 8 (2002) 1080-1084
45. Barry C.P., and Ryan C.D. Osteomyelitis of the maxilla secondary to osteopetrosis: report of a case. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 95 (2003) 12-15
46. Tarassoff P., and Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J. Oral. Maxillofac. Surg. 61 (2003) 1238-1239
47. Weinstein R.S., Jilka R.L., Parfitt A.M., and Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102 (1998) 274-282
48. Morrish Jr. R.B., Chan E., Silverman Jr. S., Meyer J., Fu K.K., and Greenspan D. Osteonecrosis in patients irradiated for head and neck carcinoma. Cancer 47 (1981) 1980-1983
49. Gemmell E., Yamazaki K., and Seymour G.J. Destructive periodontitis lesions are determined by the nature of the lymphocytic response. Crit. Rev. Oral. Biol. Med. 13 (2002) 17-34
50. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350 (2004) 1189-1199
51. Hansen T., Kirkpatrick C.J., Walter C., and Kunkel M. Increased numbers of osteoclasts expressing cysteine proteinase cathepsin K in patients with infected osteoradionecrosis and bisphosphonate-associated osteonecrosis - a paradoxical observation?. Virchows Arch. 449 (2006) 448-454
52. Hansen T., Kunkel M., Weber A., and James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J. Oral. Pathol. Med. 35 3 (2006 Mar) 155-160
53. Bedogni A., Blandamura S., Lokmic Z., Palumbo C., Ragazzo M., Ferrari F., et al. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 105 3 (2008 Mar) 358-364